Table 1.
Abstracted data from selected studies
| Author | Year | Study Design | Total N (exposed and unexposed) | N (exposed cases) | Exposure | Outcome | Risk Estimate | Lower 95% CI | Upper 95% CI | Time Period of Diagnosis | Study Population | Adjustment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Albin et al. 51 | 2000 | Case‐control | 333 cases; 351 controls | 65 | Ever | AML | 0.98 | 0.64 | 1.5 | 1976–1993 | Adults | Age, gender, and county |
| Altekruse et al. 30 | 1999 | Cohort | 547,586 | 207 | Ever | All leukemias | 1.1 | 0.9 | 1.3 | 1982–1994 | Women | Age, race, smoking, education, occupation, and self‐reported exposure to X‐ray or fluoroscopic examinations, radium, radioactive isotopes, coal tar/asphalt, diesel exhaust, dyes, gasoline exhaust, pesticides, textiles, and dusts |
| 453,302 | 69 | 1–9 years | All leukemias | 0.9 | 0.7 | 1.2 | ||||||
| 432,903 | 78 | 10–19 years | All leukemias | 1.2 | 0.9 | 1.5 | ||||||
| 409,085 | 60 | 20 + years | All leukemias | 1.3 | 1 | 1.7 | ||||||
| Benavente et al. 19 | 2005 | Case–control | 577 cases; 616 controls | 37 | Ever | CLL | 2.3 | 1.1 | 4.7 | 1998–2002 | Adults | Pathology center, gender, age, and house ownership |
| 113 cases; 520 controls | 27 | Before 1980 | CLL | 3.5 | 1.5 | 7.8 | ||||||
| 96 cases; 525 controls | 10 | After 1980 | CLL | 1.5 | 0.6 | 3.6 | ||||||
| 110 cases; 546 controls | 24 | Dark | CLL | 2.3 | 1.1 | 4.9 | ||||||
| 103 cases; 510 controls | 17 | Light | CLL | 2.9 | 1.3 | 6.8 | ||||||
| 121 cases; 589 controls | 35 | Permanent | CLL | 3.4 | 1.4 | 7.8 | ||||||
| 89 cases; 456 controls | 3 | Semi‐permanent | CLL | 1.6 | 0.4 | 6.6 | ||||||
| 92 cases; 502 controls | 6 | ≤10 years | CLL | 1.1 | 0.4 | 3 | ||||||
| 98 cases; 481 controls | 12 | 11–24 years | CLL | 3.2 | 1.3 | 8.2 | ||||||
| 105 cases; 491 controls | 19 | ≥25 years | CLL | 3.7 | 1.5 | 8.9 | ||||||
| Bjork et al. 34 | 2001 | Case‐control | 226 cases; 251 controls | 25 | Ever | CML | 0.35 | 0.18 | 0.68 | 1976–1993 | Adults | Gender, age, and county |
| Cantor et al. 52 | 1988 | Case‐control | 577 cases; 1245 controls | 43 | Ever | All leukemias | 1.8 | 1.1 | 2.7 | 1980–1983 | Men | State of residence, and age |
| 143 cases; 1245 controls | 7 | Ever | ANL | 1.1 | 0.5 | 2.6 | ||||||
| 243 cases; 1245 controls | 14 | Ever | CLL | 1.4 | 0.7 | 2.6 | ||||||
| 51 cases; 1245 controls | 5 | Ever | CML | 2.2 | 0.7 | 6.2 | ||||||
| 16 cases; 1245 controls | 2 | Ever | ALL | 2.9 | 0.4 | 13.8 | ||||||
| de Sanjose et al. 3 | 2006 | Case‐control | 407 cases; 2417 controls | 127 | Ever | CLL | 1.43 | 1.01 | 2.03 | 1998–2003 | Adults | Center, gender, educational level, home ownership, and age |
| Grodstein et al. 53 | 1994 | Cohort | 99,067 | 8 | Ever | CLL | 0.6 | 0.3 | 1.5 | 1976–1990 | Women | Age |
| 99,067 | 8 | Ever | AML/CML/ALL | 0.8 | 0.3 | 1.9 | ||||||
| Karakosta et al. 20 | 2015 | Case–control | 171 cases; 175 controls | 33 | Ever | CLL | 0.99 | 0.57 | 1.71 | NR | Adults | Age, gender, ethnicity, area of residence, and family history of malignancy |
| Markovic‐Denic et al. 50 | 1995 | Case‐control | 130 cases; 130 controls | 11 | Ever | CLL | 1.97 | 1.08 | 3.59 | 1989 | Adults | Gender, age, place of residence, area of residence, and income |
| Markowitz et al. 33 | 1985 | Case‐control | 101 cases; 101 controls | NR | Ever | ANL | 3.1 | NR | NR | 1980–1982 | Adults | Matched (unspecified) |
| Mele et al. 31 | 1994 | Case‐control | 252 cases; 1161 controls | NR | Ever | AML | 1.2 | 0.4 | 4 | 1987–1990 | Men | Age, education, and residence |
| 156 cases; 1161 controls | NR | Ever | CML | 2.1 | 0.7 | 6.2 | ||||||
| 252 cases; 1161 controls | NR | Dark | AML | 1.6 | 0.4 | 5.5 | ||||||
| 156 cases; 1161 controls | NR | Light | CML | 2 | 0.2 | 28.1 | ||||||
| 156 cases; 1161 controls | NR | Dark | CML | 2.1 | 0.6 | 7.2 | ||||||
| 252 cases; 1161 controls | NR | Ever | AML | 1 | 0.7 | 1.3 | Women | |||||
| 100 cases; 1161 controls | NR | Ever | ALL | 1.2 | 0.8 | 1.8 | ||||||
| 156 cases; 1161 controls | NR | Ever | CML | 1 | 0.6 | 1.5 | ||||||
| 252 cases; 1161 controls | NR | Light | AML | 0.7 | 0.4 | 1.2 | ||||||
| 252 cases; 1161 controls | NR | Dark | AML | 1.2 | 0.7 | 2 | ||||||
| 100 cases; 1161 controls | NR | Light | ALL | 1.4 | 0.6 | 3.1 | ||||||
| 100 cases; 1161 controls | NR | Dark | ALL | 1.2 | 0.6 | 2.5 | ||||||
| 156 cases; 1161 controls | NR | Light | CML | 1 | 0.4 | 2.1 | ||||||
| 156 cases; 1161 controls | NR | Dark | CML | 1.1 | 0.6 | 2.2 | ||||||
| 252 cases; 1161 controls | NR | ≤10 years | AML | 0.7 | 0.4 | 1.2 | ||||||
| 252 cases; 1161 controls | NR | >10 years | AML | 1.6 | 0.8 | 3 | ||||||
| 100 cases; 1161 controls | NR | ≤10 years | ALL | 1.2 | 0.6 | 2.3 | ||||||
| 100 cases; 1161 controls | NR | >10 years | ALL | 2 | 0.7 | 5.7 | ||||||
| 156 cases; 1161 controls | NR | ≤10 years | CML | 0.9 | 0.5 | 1.8 | ||||||
| 156 cases; 1161 controls | NR | >10 years | CML | 0.8 | 0.3 | 2.2 | ||||||
| Mele et al. 32 | 1995 | Case‐control | 36 cases; 1161 controls | NR | Ever | APL | 1.5 | 0.6 | 3.7 | 1986–1990 | Adults | Age, gender, education, and residence |
| 216 cases; 1161 controls | NR | Ever | Other AML | 0.8 | 0.5 | 1.3 | ||||||
| Mendelsohn et al. 21 | 2009 | Cohort | 29 | 9 | Ever | Leukemia | 0.68 | 0.31 | 1.51 | 1996–2000 | Women | Age, education, and smoking |
| 22 | 2 | 1–2 years | Leukemia | 0.31 | 0.07 | 1.31 | ||||||
| 24 | 4 | 3–4 years | Leukemia | 1.05 | 0.36 | 3.12 | ||||||
| 22 | 2 | 5–9 years | Leukemia | 1.05 | 0.24 | 4.56 | ||||||
| 21 | 1 | ≥10 years | Leukemia | 0.89 | 0.12 | 6.76 | ||||||
| Miligi et al. 54 | 1999 | Case‐control | NR | NR | Ever | Leukemia | 0.9 | 0.7 | 1.3 | NR | Adults | Age |
| NR | NR | Permanent | Leukemia | 1.2 | 0.9 | 1.7 | ||||||
| NR | NR | Dark | Leukemia | 2 | 1.1 | 3.8 | ||||||
| Miligi et al. 22 | 2005 | Case‐control | NR | 6 | Ever | Leukemia | 0.6 | 0.3 | 1.6 | NR | Men | Age and smoking |
| NR | 4 | Permanent | Leukemia | 1.2 | 0.3 | 4.1 | ||||||
| NR | 3 | Brown | Leukemia | 1.9 | 0.4 | 10.4 | ||||||
| NR | 140 | Ever | Leukemia | 1 | 0.7 | 1.3 | Women | |||||
| NR | 114 | Permanent | Leukemia | 1.2 | 0.9 | 1.6 | ||||||
| NR | 20 | Black | Leukemia | 1.9 | 1 | 3.4 | ||||||
| NR | 39 | Brown | Leukemia | 1.2 | 0.7 | 1.8 | ||||||
| NR | 10 | Red | Leukemia | 1 | 0.4 | 2.1 | ||||||
| NR | 85 | Permanent | All (excluding CLL) | 1.1 | 0.8 | 1.6 | ||||||
| NR | 38 | Non‐permanent | All (excluding CLL) | 0.9 | 0.6 | 1.4 | ||||||
| NR | 37 | Permanent | CLL | 1.5 | 0.9 | 2.4 | ||||||
| NR | 12 | Non‐permanent | CLL | 0.9 | 0.4 | 1.8 | ||||||
| NR | 43 | Blonde | Leukemia | 0.9 | 0.6 | 1.3 | ||||||
| NR | 41 | Permanent | Lymphocytic | 1.3 | 0.8 | 2.2 | ||||||
| NR | 14 | Non‐permanent | Lymphocytic | 0.9 | 0.4 | 1.6 | ||||||
| NR | 58 | Permanent | Myelocytic | 1.1 | 0.7 | 1.6 | ||||||
| NR | 24 | Non‐permanent | Myelocytic | 0.8 | 0.5 | 1.4 | ||||||
| Rauscher et al. 55 | 2004 | Case‐control | 769 cases; 623 controls | 185 | Ever | Leukemia | 1.3 | 0.99 | 1.8 | 1986–1989 | Adults | Age, race, gender, geographic region, and education |
| 596 cases; 509 controls | 12 | Temporary | Leukemia | 0.93 | 0.41 | 2.1 | ||||||
| 630 cases; 537 controls | 47 | Semi‐permanent | Leukemia | 1.1 | 0.7 | 1.7 | ||||||
| 671 cases; 546 controls | 104 | Permanent | Leukemia | 1.6 | 1.1 | 2.4 | ||||||
| 109 cases | Permanent | Lymphoblastic | 2 | 0.87 | 4.6 | |||||||
| 515 cases | Permanent | Myelocytic | 1.6 | 1.1 | 2.5 | |||||||
| 601 cases; 508 controls | 17 | 1–4 years (permanent) | Leukemia | 1.6 | 0.6 | 2.9 | ||||||
| 600 cases; 511 controls | 16 | 1–4 years (semi‐permanent) | Leukemia | 1 | 0.48 | 2.1 | ||||||
| 613 cases; 515 controls | 29 | 5–14 years (permanent) | Leukemia | 1.5 | 0.78 | 2.7 | ||||||
| 608 cases; 514 controls | 24 | 5–14 years (semi‐permanent) | Leukemia | 1.3 | 0.67 | 2.5 | ||||||
| 623 cases; 516 controls | 39 | ≥15 years (permanent) | Leukemia | 1.9 | 1.1 | 3.6 | ||||||
| 605 cases; 516 controls | 21 | ≥15 years (semi‐permanent) | Leukemia | 1 | 0.52 | 2 | ||||||
| 604 cases; 522 controls | 50 | Light (permanent) | Leukemia | 1.8 | 1.1 | 3.1 | ||||||
| 609 cases; 511 controls | 25 | Dark (permanent) | Leukemia | 1.6 | 0.78 | 3.2 | ||||||
| 606 cases; 522 controls | 22 | Light (semi‐permanent) | Leukemia | 0.79 | 0.42 | 1.5 | ||||||
| 612 cases; 519 controls | 28 | Dark (semi‐permanent) | Leukemia | 1.2 | 0.65 | 2.1 | ||||||
| 629 cases; 522 controls | 45 | Before 1970 (permanent) | Leukemia | 1.7 | 0.98 | 3 | ||||||
| 611 cases; 512 controls | 27 | 1970–1979 (permanent) | Leukemia | 1.6 | 0.83 | 3.1 | ||||||
| 597 cases; 506 controls | 13 | After 1979 (permanent) | Leukemia | 1.2 | 0.51 | 2.9 | ||||||
| 621 cases; 519 controls | 37 | Before 1970 (semi‐permanent) | Leukemia | 1.6 | 0.87 | 2.8 | ||||||
| 603 cases; 515 controls | 19 | 1970–1979 (semi‐permanent) | Leukemia | 0.98 | 0.5 | 1.9 | ||||||
| 589 cases; 508 controls | 5 | After 1979 (semi‐permanent) | Leukemia | 0.41 | 0.14 | 1.2 | ||||||
| Sandler et al. 56 | 1993 | Case‐control | 615 cases; 630 controls | NR | Ever | Leukemia | 1.5 | 1.1 | 2.1 | NR | Adults | Age, race, gender, smoking, and income |
| NR | NR | Permanent | Leukemia | 1.6 | 1 | 2.4 | ||||||
| NR | NR | Semi‐permanent | Leukemia | 1.4 | 0.9 | 2.1 | ||||||
| NR | NR | Temporary | Leukemia | 1.2 | 0.3 | 4 | ||||||
| NR | NR | ≥16 years | Leukemia | 2.6 | NR | NR | ||||||
| Skibola et al. 23 | 2014 | Case‐control | 38 cases; 4680 controls | 27 | Ever | ALL | 1 | 0.48 | 2.11 | NR | Adults | Age and gender |
| 13 cases; 2100 controls | 2 | Temporary | ALL | 2 | 0.36 | 11.02 | ||||||
| 35 cases; 4245 controls | 24 | Permanent | ALL | 0.94 | 0.44 | 2.03 | ||||||
| 22 cases; 2654 controls | 11 | Light | ALL | 1.39 | 0.57 | 3.34 | ||||||
| 24 cases; 3523 controls | 13 | Dark | ALL | 0.82 | 0.35 | 1.89 | ||||||
| 23 cases; 2650 controls | 12 | 1–8 years | ALL | 0.83 | 0.34 | 2.02 | ||||||
| 19 cases; 2413 controls | 8 | 9–19 years | ALL | 1.06 | 0.40 | 2.80 | ||||||
| 14 cases; 2491 controls | 3 | 20+ years | ALL | 0.7 | 0.18 | 2.71 | ||||||
| 16 cases; 2863 controls | 5 | Before 1980 | ALL | 1.07 | 0.33 | 3.5 | ||||||
| 30 cases; 2702 controls | 19 | After 1980 | ALL | 1.23 | 0.5 | 3 | ||||||
| Slager et al. 24 | 2014 | Case‐control | 404 cases; 4122 controls | 284 | Ever | CLL/SLL | 1.08 | 0.86 | 1.37 | Until 2011 | Adults | Age, gender, race, and study |
| 134 cases; 1447 controls | 14 | Temporary | CLL/SLL | 0.74 | 0.41 | 1.34 | ||||||
| 379 cases; 3621 controls | 259 | Permanent | CLL/SLL | 1.16 | 0.91 | 1.48 | ||||||
| 218 cases; 2135 controls | 98 | Light | CLL/SLL | 1.13 | 0.84 | 1.51 | ||||||
| 292 cases; 2918 controls | 172 | Dark | CLL/SLL | 1.11 | 0.86 | 1.44 | ||||||
| 192 cases; 2162 controls | 72 | 1–8 years | CLL/SLL | 1 | 0.71 | 1.42 | ||||||
| 191 cases; 1918 controls | 71 | 9–19 years | CLL/SLL | 1.22 | 0.86 | 1.72 | ||||||
| 215 cases; 2011 controls | 95 | ≥20 years | CLL/SLL | 1.26 | 0.92 | 1.73 | ||||||
| 247 cases; 2136 controls | 127 | Before 1980 | CLL/SLL | 1.36 | 1 | 1.86 | ||||||
| 216 cases; 2231 controls | 96 | After 1980 | CLL/SLL | 1.06 | 0.76 | 1.46 | ||||||
| Thun et al. 29 | 1994 | Cohort | 85 | 16 | Ever | Lymphoid | 0.77 | 0.44 | 1.35 | 1982–1989 | Women | Age |
| 74 | 5 | 1–9 years | Lymphoid | 0.71 | 0.27 | 1.86 | ||||||
| 76 | 7 | 10–19 years | Lymphoid | 0.91 | 0.4 | 2.08 | ||||||
| 73 | 4 | ≥20 years | Lymphoid | 0.67 | 0.24 | 1.86 | ||||||
| 198 | 49 | Ever | Myeloid and Monocytic | 0.93 | 0.67 | 1.3 | ||||||
| 169 | 20 | 1–9 years | Myeloid and Monocytic | 1.02 | 0.61 | 1.69 | ||||||
| 168 | 19 | 10–19 years | Myeloid and Monocytic | 0.97 | 0.6 | 1.58 | ||||||
| 159 | 10 | ≥20 years | Myeloid and Monocytic | 0.79 | 0.42 | 1.51 | ||||||
| 82 | 18 | Ever | Other | 1.01 | 0.57 | 1.79 | ||||||
| 73 | 9 | 1–9 years | Other | 1.66 | 0.76 | 3.61 | ||||||
| 71 | 7 | 10–19 years | Other | 0.87 | 0.38 | 2.02 | ||||||
| 66 | 2 | ≥20 years | Other | 0.47 | 0.11 | 2.08 | ||||||
| Vedel‐Krogh et al. 25 | 2016 | Cohort | 45 | 5 | Ever | Leukaemia | 0.40 | 0.16 | 1.02 | 1976–1978 | Women | Age, birth year, BMI, smoking, alcohol, physical activity, marital status, education, income, systolic blood pressure, cholesterol, triglycerides, glucose, FEV1, and FEV1/FVC |
| Wong et al. 27 | 2009 | Case‐control | 263 cases; 530 controls | NR | Ever | AML | 0.98 | 0.8 | 1.2 | 2003–2007 | Adults | Age and gender |
| Wong et al. 28 | 2010 | Case‐control | 15 cases; 56 controls | NR | Ever | CLL/SLL | 0.37 | 0.18 | 0.76 | 2003–2008 | Adults | Age and gender |
| Zahm et al. 57 | 1992 | Case‐control | 37 cases; 723 controls | 3 | Ever | CLL | 1 | 0.2 | 3.8 | 1983–1986 | Men | Age |
| 35 cases; 682 controls | 1 | Semi or non‐permanent | CLL | 3.2 | 0.1 | 28.6 | ||||||
| 19 cases; 695 controls | 9 | Ever | CLL | 1 | 0.3 | 2.6 | Women | |||||
| 17 cases; 623 controls | 7 | Semi or non‐permanent | CLL | 0.9 | 0.3 | 2.8 | ||||||
| 12 cases; 482 controls | 2 | Permanent | CLL | 0.8 | 0.1 | 4 | ||||||
| 11 cases; 414 controls | 1 | Blonde (semi‐ or nonpermanent) | CLL | 1.1 | 0.05 | 9.1 | ||||||
| 14 cases; 511 controls | 4 | Brown/brunette (semi‐ or nonpermanent) | CLL | 1 | 0.3 | 3.6 | ||||||
| 12 cases; 416 controls | 2 | Brown/brunette (permanent) | CLL | 1.8 | 0.3 | 9.9 | ||||||
| Zhang et al. 26 | 2008 | Case‐control | 324 cases | 244 | Ever | CLL/SLL | 1.3 | 1 | 1.6 | 1988–2003 | Women | Age, race, and study center |
| 243 cases | 163 | Permanent | CLL/SLL | 1.2 | 0.9 | 1.6 | ||||||
| 181 cases | 101 | Nonpermanent | CLL/SLL | 1.3 | 0.9 | 1.7 | ||||||
| 228 cases | 148 | Dark | CLL/SLL | 1.2 | 0.9 | 1.7 | ||||||
| 184 cases | 104 | Light | CLL/SLL | 1.3 | 0.9 | 1.8 | ||||||
| 239 cases | 159 | Before 1980 | CLL/SLL | 1.5 | 1.1 | 2 | ||||||
| 164 cases | 84 | After 1980 | CLL/SLL | 1.3 | 1 | 1.7 | ||||||
| NR | NR | ≥20 years | CLL/SLL | 1.3 | 1 | 1.8 |
AML, acute myeloid leukemia; ALL, acute lymphocytic leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; NR, not reported.